Amarin Corporation PLC (AMRN) Upgraded by ValuEngine to Hold
ValuEngine upgraded shares of Amarin Corporation PLC (NASDAQ:AMRN) from a sell rating to a hold rating in a research report released on Thursday.
A number of other brokerages have also recently issued reports on AMRN. Jefferies Group LLC reissued a buy rating and issued a $5.00 target price on shares of Amarin Corporation PLC in a research report on Monday, June 12th. BidaskClub cut shares of Amarin Corporation PLC from a sell rating to a strong sell rating in a research report on Thursday, August 24th. Zacks Investment Research cut shares of Amarin Corporation PLC from a buy rating to a hold rating in a research report on Monday, August 7th. HC Wainwright reissued a buy rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a research report on Wednesday, August 9th. Finally, Cantor Fitzgerald set a $10.00 target price on shares of Amarin Corporation PLC and gave the company a buy rating in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $7.35.
Amarin Corporation PLC (AMRN) traded down 1.18% during trading on Thursday, hitting $3.35. 489,175 shares of the stock were exchanged. The firm has a 50-day moving average of $3.56 and a 200-day moving average of $3.32. Amarin Corporation PLC has a 52 week low of $2.56 and a 52 week high of $4.47. The stock’s market capitalization is $907.15 million.
Amarin Corporation PLC (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million during the quarter, compared to analyst estimates of $40.35 million. During the same quarter in the prior year, the firm earned ($0.07) earnings per share. Amarin Corporation PLC’s revenue for the quarter was up 37.0% on a year-over-year basis. Equities research analysts anticipate that Amarin Corporation PLC will post ($0.21) earnings per share for the current fiscal year.
In other news, General Counsel Joseph T. Kennedy sold 307,911 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $4.00, for a total value of $1,231,644.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.72% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Airain ltd boosted its stake in Amarin Corporation PLC by 382.9% in the second quarter. Airain ltd now owns 87,122 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 69,081 shares in the last quarter. Perkins Capital Management Inc. boosted its stake in Amarin Corporation PLC by 20.3% in the second quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 7,000 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Amarin Corporation PLC during the first quarter valued at $960,000. Renaissance Technologies LLC boosted its stake in Amarin Corporation PLC by 348.2% in the first quarter. Renaissance Technologies LLC now owns 1,730,200 shares of the biopharmaceutical company’s stock valued at $5,537,000 after buying an additional 1,344,200 shares in the last quarter. Finally, Morgan Stanley boosted its stake in Amarin Corporation PLC by 119.7% in the first quarter. Morgan Stanley now owns 1,138,992 shares of the biopharmaceutical company’s stock valued at $3,645,000 after buying an additional 620,577 shares in the last quarter. 37.76% of the stock is owned by institutional investors.
Amarin Corporation PLC Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.